

McGill study promises faster-acting antidepressants

5 September 2007

A McGill University study has found that a new class of drugs known as serotonin₄ (5-HT₄) receptor agonists may take effect four to seven times faster than traditional selective serotonin reuptake inhibitors (SSRIs). The study, led by former McGill post-doctoral fellow in psychiatry Guillaume Lucas with his supervisor, the late Dr. Guy Debonnel, was published in the September 6 issue of the journal Neuron.

Existing SSRI-class drugs, widely prescribed as anti-depressants, can take up to six weeks to become effective, with potentially serious clinical consequences. Dr. Lucas, now an associate researcher at the Centre de Recherche Fernand Séguin of Université de Montréal, said, "These delays are not only a matter of patient comfort, it's really important, especially when you are treating major depressions that could lead to suicide."

SSRIs work by enhancing the available concentration of the neurotransmitter serotonin in the brain. The McGill study focused on a new class of drugs known as serotonin₄ (5-HT₄) receptor agonists, which act directly on the nerve impulses of serotonin neurons.

In behavioral tests, rats on two different serotonin₄ receptor agonists showed marked improvements in symptoms of chronic depression after only three days and were symptom-free after a week. In subsequent tests, three days of treatment with serotonin₄ receptor agonists induced anti-depressant-related effects in the brains of the animals seen only after weeks of treatments with SSRIs.

Source: McGill University

APA citation: McGill study promises faster-acting anti-depressants (2007, September 5) retrieved 3 May 2021 from https://medicalxpress.com/news/2007-09-mcgill-faster-acting-anti-depressants.html



This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.